CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum.

Background: According to recent studies, amyloid- (A) isoforms as cerebrospinal fluid (CSF) biomarkers have remarkable predictive value for cognitive decline in the early stages of Alzheimer's disease (AD). Herein, we aimed to investigate the correlations between several targeted proteomics in CSF samples with A ratios and cognitive scores in patients in AD spectrum to search for potential early diagnostic utility.

Methods: A total of 719 participants were found eligible for inclusion.